Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC

BACKGROUND: After early-line (first- and second-line) endocrine therapy, hormone-receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancers (mBCs) become resistant to endocrine therapy. Genetic alterations may underlie resistance to endocrine therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Yu, Li, Jing, Liu, Binliang, Ran, Jialu, Hu, Zhe-Yu, Ouyang, Quchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742482/
https://www.ncbi.nlm.nih.gov/pubmed/36518248
http://dx.doi.org/10.3389/fendo.2022.1075830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742482/
https://www.ncbi.nlm.nih.gov/pubmed/36518248
http://dx.doi.org/10.3389/fendo.2022.1075830

Ejemplares similares